HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanotto, Valentina, Ongaro, Elena, Rihawi, Karim, Avallone, Antonio, Silvestris, Nicola, Fornaro, Lorenzo, Vasile, Enrico, Antonuzzo, Lorenzo, Leone, Francesco, Rosati, Gerardo, Giuliani, Francesco, Bordonaro, Roberto, Scartozzi, Mario, Maglio, Giovanna De, Negri, Francesca V., Fasola, Gianpiero, Aprile, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356612/
https://www.ncbi.nlm.nih.gov/pubmed/27542243
http://dx.doi.org/10.18632/oncotarget.11264
Descripción
Sumario:HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.

Ejemplares similares